Jounce Therapeutics Inc. rose to the head of the pack of early 2017 biopharma IPOs by pricing an upsized offering of 6.365 million shares at $16 apiece, above the intended range of $13 to $15, for proceeds of $101.8 million, up from its proposed $75 million raise.